Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name?

被引：0
|
作者：
Grant, S
Dent, P
机构：
[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2004年 / 3卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：873 / 875
页数：3
相关论文
共 50 条
  • [31] Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
    Schwartz, GK
    Ilson, D
    Saltz, L
    O'Reilly, E
    Tong, W
    Maslak, P
    Werner, J
    Perkins, P
    Stoltz, M
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) : 1985 - 1992
  • [32] Uptake and metabolism of the cyclin-dependent kinase inhibitor flavopiridol in cultured mouse osteoblasts:: Implications on therapy.
    Hoffmann, O
    Hagenauer, B
    Haslmayer, P
    Thalhammer, T
    Jäger, W
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S407 - S407
  • [33] Cyclin-dependent kinase 4 inhibitor a and tumor
    Gong, Z.
    Fu, J.
    Chinese Journal of Medical Genetics, 2001, 18 (03) : 219 - 221
  • [34] The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis
    Miyashita, Kazumi
    Shiraki, Katsuya
    Fuke, Hiroyuki
    Inoue, Tomoko
    Yamanaka, Yutaka
    Yamaguchi, Yumi
    Yamamoto, Norihiko
    Ito, Keiichi
    Sugimoto, Kazushi
    Nakano, Takeshi
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2006, 18 (02) : 249 - 256
  • [35] Cyclin-dependent kinase inhibitor, flavopiridol, sensitizes human hepatocelluler carcinoma cells to trail-induced apoptosis
    Miyashita, K
    Shiraki, K
    Fuke, H
    Inoue, T
    Yamanaka, Y
    Yamaguchi, YUMI
    Saitou, Y
    Sugimoto, K
    Nakano, T
    JOURNAL OF HEPATOLOGY, 2005, 42 : 108 - 109
  • [36] ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Mahoney, Emilia
    Lucas, David M.
    Gupta, Sneha V.
    Wagner, Amy J.
    Herman, Sarah E. M.
    Smith, Lisa L.
    Yeh, Yuh-Ying
    Andritsos, Leslie
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Blum, Kristie A.
    Zhang, Xiaoli
    Lehman, Amy
    Kong, Hui
    Gurcan, Metin
    Grever, Michael R.
    Johnson, Amy J.
    Byrd, John C.
    BLOOD, 2012, 120 (06) : 1262 - 1273
  • [37] Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
    Senderowicz, AM
    Headlee, D
    Stinson, SF
    Lush, RM
    Kalil, N
    Villalba, L
    Hill, K
    Steinberg, SM
    Figg, WD
    Tompkins, A
    Arbuck, SG
    Sausville, EA
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 2986 - 2999
  • [38] Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of human esophageal adenocarcinorna cells by inhibiting DNA repair
    Raju, U.
    Koto, M.
    Lu, X.
    Ajani, J.
    Hittelman, W.
    EJC SUPPLEMENTS, 2006, 4 (12): : 152 - 153
  • [39] The cyclin-dependent kinase inhibitor flavopiridol potentiates γ-irradiation-induced apoptosis in colon and gastric cancer cells
    Jung, C
    Motwani, M
    Kortmansky, J
    Sirotnak, FM
    She, YH
    Gonen, M
    Haimovitz-Friedman, A
    Schwartz, GK
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6052 - 6061
  • [40] Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Schwartz, GK
    O'Reilly, E
    Ilson, D
    Saltz, L
    Sharma, S
    Tong, W
    Maslak, P
    Stoltz, M
    Eden, L
    Perkins, P
    Endres, S
    Barazzoul, J
    Spriggs, D
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2157 - 2170
12345